NEW YORK, Feb. 19, 2015 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTC:AXIM), an industry leader in cannabinoid research and industrial hemp product development, is proud to announce that it has plans to revitalize the cosmetics industry with the launch of its new hemp cannabinoid-based Cosmetics Division.
"In the skin care market there is a need for innovative, rejuvenating products based on organic, agricultural ingredients, which will provide cosmetic benefits to the consumer," states George E. Anastassov, MD, DDS, MBA and AXIM's Chief Executive Officer. "With our exclusive cannabinoid-based product formulations, we believe that AXIM's RENECANN™ line will successfully satisfy the needs of even the most demanding consumers."
AXIM has filed a provisional patent covering numerous formulations for skin care products. These formulations will be targeted at the daily use market. The products planned to be included in the Cosmetics Division product line will be the following:
- Anti-Aging Day Cream
- Anti-Aging Night Cream
- Hand and Nail Cream
- Eye Cream
- Lip Balm
- Baby Diaper Rash Cream
- Anti-Acne Tonic
- Anti-Acne Cream
- Face Wash
- Body Wash
- Anti-Dandruff Shampoo
- Deodorant Spray
To AXIM, processing industrial hemp for everyday use applications is an art. The Company understands that industrial hemp contains numerous non-psychoactive cannabinoids and essential amino-acids. These are ideal moisturizers, lubricants, anti-inflammatory agents, antibacterial and rejuvenating agents. The Cosmetics Division within AXIM will offer hemp oil-derived, cannabinoid-containing, rejuvenating skin care products targeted at unique solutions for the general population.
Anastassov concludes, "Our team of cosmetic chemists possess over 30 years of experience producing world-renowned lines of skin care products. We believe that RENECANN™ will be the pinnacle of these efforts. At AXIM we believe that the new Cosmetic Division will bring substantial, palpable benefits to consumers and will become an important part of the Company in the future."
Through unique proprietary delivery mechanisms for the introduction of cannabinoids (i.e. CBD, CBG, among others), AXIM is focused upon finding solutions for conditions for which there is currently no effective treatment. The Company's initiatives encompass the complete use of the hemp plant leaving a net negative carbon footprint on the environment.
To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@CMWmedia.com or call 858-380-5478.
AXIM Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products.
CONTACT: North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227
Source:AXIM Biotechnologies, Inc